Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting LDL-C to Less Than 0.8 mmol/L in Patients After PCI With High Risk of Cardiovascular Disease: an Open-label, Assessor-blinded, Randomized Trial (REC-SAFETARGET Trial)

NCT06821711 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT06821711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06821711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting LDL-C to Less Than 0.8 mmol/L in Patients After PCI With High Risk of Cardiovascular Disease: an Open-label, Assessor-blinded, Randomized Trial (REC-SAFETARGET Trial)
Lead sponsor
Xijing Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 20, 2025
Completion date
August 15, 2029
Enrollment
12,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndromes, chronic coronary syndrome, high risk patient, percutaneous coronary intervention